u/elin_ferrari

the concentration on the vial in marker is the most important step

API source questions are on-topic and compounders dodging them is newsworthy

Inter-lab variance on this kind of assay is routinely 1–2 points. Different column, different gradient, different integration.

the heart rate signal is real in the data

it is in the wiki actually

Counter-anecdote: opposite result, same dose. Which mostly tells us the variance is huge.

The QYB lane used to be 13 days, now averaging 9. Carrier change or route congestion, unclear.

Rodent data is rodent data. Dose scaling is not linear and the models tell you what to investigate, not what to expect.

Cosigning the evidence standard. Receipts make the community.

I am going to push back on this slightly.

the dual agonism hits different and that is why people describe it differently

Cosigning. The GIP contribution is real and the side effects are not simply scaled versions.

Did they tell you their API source or dodge the question?

Ireland to Ireland: TFC with 22 days is the average, variance is 9

Disagree on that part. 93.7% and 99.3% on the same vial is normal.

The WWB lane used to be 23 days, now averaging 11. Carrier change or route congestion, unclear.

DHL was 16 days door-to-door but shipping. EMS took 40 days but cheaper and fine.

positive and negative reports both need the same evidence standard

Slight fix: the number was 98.7, not 98.3. Decimal point, but a fairly consequential one.

Strongly agree. Customs adds unpredictable delay.

lane reports need origin, destination, carrier, actual transit days

Counter-anecdote: opposite result, same dose. Which mostly tells us the variance is huge.

That is net peptide content, not purity. Different number, different meaning.